Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$45.36 USD
-1.73 (-3.67%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $45.37 +0.01 (0.02%) 7:20 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Agios Pharmaceuticals (AGIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$53.67 | $60.00 | $46.00 | 13.97% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Agios Pharmaceuticals comes to $53.67. The forecasts range from a low of $46.00 to a high of $60.00. The average price target represents an increase of 13.97% from the last closing price of $47.09.
Analyst Price Targets (6 )
Broker Rating
Agios Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.63 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AGIO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.63 | 1.63 | 1.63 | 1.63 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
8/1/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
6/4/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/3/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
4/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.63 |
ABR (Last week) | 1.63 |
# of Recs in ABR | 8 |
Average Target Price | $53.67 |
LT Growth Rate | 12.00% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | 0.05 |